Pharmaceutical

Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker

Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has alw...

Dec 11, 2023

How Laurie Glimcher ended up taking the greatest risk of her career: breaking up...

STAT+: GE HealthCare CEO named chair of AdvaMed as device lobby forms new imaging division

STAT+: GE HealthCare CEO named chair of AdvaMed as devi...

Dec 11, 2023

AdvaMed has named GE HealthCare CEO Peter Arduini as its new chair. The medical ...

STAT+: NEJM aims to hold AI to account with new publication

STAT+: NEJM aims to hold AI to account with new publica...

Dec 11, 2023

The New England Journal of Medicine is launching NEJM AI, an online-only publica...

Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast

Morning Rounds: Preterm birth rates vary across the U.S...

Dec 11, 2023

Understand how science, health policy, and medicine shape the world everyday. Si...

The biotech news you missed from the weekend

The biotech news you missed from the weekend

Dec 11, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence

STAT+: Pharmalittle: Bluebird’s sickle-cell screwups ma...

Dec 11, 2023

Bluebird Bio mispriced its sickle cell gene therapy and fumbled a pivotal financ...

STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds

STAT+: The prices of 8 drugs were hiked without proof o...

Dec 11, 2023

During 2022, drugmakers substantially raised prices on eight widely used medicin...

STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year

STAT+: Amid fears of superbugs, sales of antibiotics us...

Dec 11, 2023

Amid fears of superbugs, the sale of medically important antibiotics given to fo...

STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale

STAT+: After sickle-cell screwups, Bluebird Bio’s only ...

Dec 11, 2023

The approval of Bluebird Bio’s sickle cell treatment should have been a momentum...

STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers

STAT+: Inside Vertex’s decades-long quest to develop a ...

Dec 11, 2023

The biotech industry has tried — and repeatedly failed — to develop new and effe...

Opinion: U.S. medical schools aren’t teaching future doctors about 7.4 million of their patients

Opinion: U.S. medical schools aren’t teaching future do...

Dec 11, 2023

A medical student and twin sister of a man with profound autism argues future do...

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

STAT+: A Q&A with Vertex founder Joshua Boger on Casgev...

Dec 11, 2023

Vertex made history Friday when it received regulatory approval for a CRISPR-bas...

Hisamitsu Pharmaceutical sees highest patent filings an...

Dec 10, 2023

Hisamitsu Pharmaceutical saw the highest growth of 199% in patent filings and 26...

Lupin sees highest patent filings and grants during Sep...

Dec 10, 2023

Lupin saw the highest growth of 199% in patent filings in August and 149% in gra...

Cosmo Pharmaceuticals sees highest patent filings and g...

Dec 10, 2023

Cosmo Pharmaceuticals saw the highest growth of 399% in patent filings and 499% ...

Otsuka sees highest patent filings and grants during Ju...

Dec 10, 2023

Otsuka saw the highest growth of 95% in patent filings in August and 104% in gra...